K-18 conjugate (K18)

05/01/1986 - "This remarkable efficacy and low degree of side effects in clinical application is probably due to the higher affinity and accumulation of K18 in the tumor region. "
03/01/1990 - "A distribution study clarified the unique properties of K18 to accumulate and remain in the tumor site with a high rate."
02/01/1988 - "[Clinical phase II study of K-18 in cancer of the digestive organs]."
05/01/1986 - "In a study of distribution after K18 administration, the accumulation and retention of this drug in the tumor region were observed. "
01/01/2013 - "The extracts from Halomonas meridiana (P3-37B), Chromohalobacter israelensis (K18) and Idiomarina loihiensis (P3-37C) were unable to induce any change in MMP in HeLa cancer cells, and thus suggested mitochondria-independent apoptosis induction. "

05/01/2003 - "Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter."
09/01/1982 - "K9, K11, K13, K16, K18, K19, K20, K62, K64, K82, were isolated, both as pure cultures and in association with other organisms, from the foci of inflammation in the pulmonary tissue in acute pneumonia. "
04/01/2015 - "All keratins were overexpressed in subjects with moderate vs. minimal inflammation, while K7, K8 and K18 were upregulated in patients with advanced liver fibrosis. "
01/01/2015 - "Acute inflammation resulted in reduced K8, K18, K19 and VIM (all p<0.05) compared to controls and non inflamed mucosa; reduced levels of if- associated proteins were also seen in DT and DR. Increased levels of keratins in LSPC was noted relative to controls or ROUC (K8, K18, K19 and VIM, p<0.05). "

04/01/1987 - "We suggest that the combination of K18 with prednisolone may be effective for multiple myeloma which is unresponsive to treatment with anticancer drugs."
04/01/1987 - "[A case of multiple myeloma responding very well to the combination of K18 with prednisolone]."
12/01/1988 - "Clinical experience of K18 (IgG-melphalan) for five cases of refractory multiple myeloma."

02/01/1991 - "K-18 is an antitumor agent with minimal side effects, and seems to be effective for RAEB with hypoplastic marrow."
02/01/1991 - "A 63-year-old male with refractory anemia with excess of blasts (RAEB) and hypoplastic marrow was treated with K-18 (240 mg/day P.O.). "
02/01/1991 - "[A remarkable effect of K-18 (IgG-melphalan complex) in a case of RAEB with hypoplastic marrow]."

04/01/2012 - "Moreover, studies showed an association of K8/K18 variants with human acute and chronic liver diseases. "
05/01/2006 - "For example, one study showed no amino acid-altering K8/K18 mutations in 256 German patients with liver disorders, while another found 58 out of 467 American liver disease patients with K8/K18 mutations. "
05/01/2012 - "K8/K18 variants are found in approximately 4% of white population and predispose to development and adverse outcome of multiple liver diseases. "
09/01/2010 - "Mutations in K8 and K18 predispose the affected individual to liver disease as they protect hepatocytes from apoptosis. "
08/01/2009 - "K8/K18/K19 variants are overrepresented in Italian PBC patients and associate with liver disease progression. "